Provision of a Drug Deactivation System for Unused Opioid Disposal at Surgical Dismissal: Opportunity to Reduce Community Opioid Supply.

Objective: To determine the impact of a drug deactivation system to post-surgical patients on the rate of opioid prescription disposal.

Patients And Methods: Two hundred post-operative patients discharged after inpatient surgery at a large academic medical center. This study was conducted August 20, 2018, through November 30, 2018.

A randomized controlled clinical trial comparing small buccal dehiscence defects around dental implants treated with guided bone regeneration or left for spontaneous healing.

Purpose: The aim of the present randomized controlled clinical study was to test whether small bony dehiscence defects (≤5 mm) left to heal spontaneously result in the same clinical and radiological outcome as defects treated with guided bone regeneration (GBR).

Materials And Methods: Twenty-two patients who received at least one implant with a small bony dehiscence defect were enrolled in the study. If the defect height was ≤5 mm, the site was randomly assigned to either the spontaneous healing (SH) group or the GBR group.

Surface roughness of dental implants and treatment time using six different implantoplasty procedures.

Objectives: To test whether or not one of six implantoplasty procedures is superior to the others rendering a minimal final implant surface roughness and a short treatment time.

Material And Methods: Forty-two one-piece implants were embedded in epoxy resin blocks with 6-mm rough implant surface exposed. The following implantoplasty polishing sequences were applied: Brownie(®) , Greenie(®) sequence (BG) (diamond rotary instruments 106-, 40-, 15-μm grit, Brownie(®) , Greenie(®) silicone polishers); Arkansas stone sequence (AS) (diamond 106-, 40-, 15-μm grit, Arkansas stone torpedo-shaped bur); Short diamond sequence (SD) (diamond 106-, 40-, 4-μm grit); Short diamond sequence with Greenie(®) (SDG) (diamond 106-, 40-, 4-μm grit, Greenie(®) ); Complete diamond sequence (CD) (diamond 106-, 40-, 15-, 8-, 4-μm grit); Complete diamond sequence with Greenie(®) (CDG) (106-, 40-, 15-, 8-, 4-μm grit, Greenie(®) ).

A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients.

Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients.